6fgt: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6fgt' size='340' side='right' caption='[[6fgt]], [[Resolution|resolution]] 2.00Å' scene=''> | <StructureSection load='6fgt' size='340' side='right' caption='[[6fgt]], [[Resolution|resolution]] 2.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6fgt]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FGT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6FGT FirstGlance]. <br> | <table><tr><td colspan='2'>[[6fgt]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FGT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6FGT FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=D9T:~{N}-[(1-azanylcyclohexyl)methyl]-1-methyl-6-oxidanylidene-pyridine-3-carboxamide'>D9T</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=D9T:~{N}-[(1-azanylcyclohexyl)methyl]-1-methyl-6-oxidanylidene-pyridine-3-carboxamide'>D9T</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6fg6|6fg6]], [[6fgf|6fgf]], [[6fgg|6fgg]], [[6fgh|6fgh]], [[6fgi|6fgi]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6fg6|6fg6]], [[6fgf|6fgf]], [[6fgg|6fgg]], [[6fgh|6fgh]], [[6fgi|6fgi]]</td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">BAZ2B, KIAA1476 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6fgt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6fgt OCA], [http://pdbe.org/6fgt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6fgt RCSB], [http://www.ebi.ac.uk/pdbsum/6fgt PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6fgt ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6fgt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6fgt OCA], [http://pdbe.org/6fgt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6fgt RCSB], [http://www.ebi.ac.uk/pdbsum/6fgt PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6fgt ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| Line 23: | Line 24: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Caflisch, A]] | [[Category: Caflisch, A]] | ||
[[Category: Lolli, G]] | [[Category: Lolli, G]] | ||
Latest revision as of 11:00, 29 August 2018
Crystal Structure of BAZ2B bromodomain in complex with 1-methylpyridinone compound 3Crystal Structure of BAZ2B bromodomain in complex with 1-methylpyridinone compound 3
Structural highlights
Function[BAZ2B_HUMAN] May play a role in transcriptional regulation interacting with ISWI. Publication Abstract from PubMedThe bromodomain-containing protein BAZ2A is a validated target in prostate cancer, while the function of its paralog BAZ2B is still undefined. The bromodomains of BAZ2A and BAZ2B have a very similar binding site for their natural ligand, the acetylated lysine side chain. Here, we present an analysis of the binding modes of eight compounds belonging to three distinct chemical classes. For all compounds, the moiety mimicking the natural ligand makes essentially identical interactions in the BAZ2A and BAZ2B bromodomains. In contrast, the rest of the molecule is partially solvent exposed and shows different orientations and interactions in the two bromodomains. Some of these differences could be exploited for designing selective inhibitors within the BAZ2 bromodomain subfamily. Structural Analysis of Small Molecule Binding to the BAZ2A and BAZ2B Bromodomains.,Dalle Vedove A, Spiliotopoulos D, D'Agostino VG, Marchand JR, Unzue A, Nevado C, Lolli G, Caflisch A ChemMedChem. 2018 May 17. doi: 10.1002/cmdc.201800234. PMID:29770599[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||||